Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)
AUTHORS
Noreen Fulton, B.S. / Jeffrey Johnson, M.S. / Lawrence D. Kaplan, M.D. / Greg Koval, B.S. / Greg Malnassy, B.S. / Sin-Ho Jung, Ph.D. / Steve Devine, M.D. / Thomas C. Shea, M.D. / John P. Leonard, M.D. / Bruce D. Cheson, M.D. / Wendy Stock, M.D.
